Who are SHR8028 eye drops's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DE-108.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/shr8028-eye-drops.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

SHR8028 eye drops — Competitive Intelligence Brief

SHR8028 eye drops (SHR8028 eye drops) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ROCK inhibitor. Area: Ophthalmology.

phase 3 ROCK inhibitor ROCK (Rho-associated coiled-coil-containing protein kinase) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

SHR8028 eye drops (SHR8028 eye drops) — Jiangsu HengRui Medicine Co., Ltd.. SHR8028 is a selective rho-associated protein kinase (ROCK) inhibitor administered as eye drops to reduce intraocular pressure in glaucoma.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
SHR8028 eye drops TARGET	SHR8028 eye drops	Jiangsu HengRui Medicine Co., Ltd.	phase 3	ROCK inhibitor	ROCK (Rho-associated coiled-coil-containing protein kinase)
DE-108	DE-108	Santen Pharmaceutical Co., Ltd.	phase 3	ROCK inhibitor	ROCK (Rho-associated coiled-coil-containing protein kinase)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ROCK inhibitor class)

Aldeyra Therapeutics, Inc. · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Santen Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SHR8028 eye drops — Competitive Intelligence Brief. https://druglandscape.com/ci/shr8028-eye-drops. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab